Bibliographic Details
| Title: |
Do patients with migraine and obesity receive different treatments? Insights from real‐world data. |
| Authors: |
Pardo, Keshet (AUTHOR), Mermelstein, Maor (AUTHOR), Tsur, Gal (AUTHOR), Yust‐Katz, Shlomit (AUTHOR) |
| Source: |
Headache: The Journal of Head & Face Pain. Jan2026, Vol. 66 Issue 1, p88-95. 8p. |
| Subjects: |
Migraine prevention, Prevention of obesity, Databases, Risk assessment, Chronic pain, Medical prescriptions, Body mass index, Topiramate, Medical care, Probability theory, Multiple regression analysis, Retrospective studies, Duloxetine, Descriptive statistics, Chi-squared test, Mann Whitney U Test, Cardiovascular diseases risk factors, Longitudinal method, Amitriptyline, Odds ratio, Pain management, Opioid analgesics, Medical records, Acquisition of data, Statistics, Nonopioid analgesics, Comparative studies, Data analysis software, Confidence intervals, Migraine, Obesity, Social stigma, Comorbidity, Sympatholytic agents |
| Geographic Terms: |
Israel |
| Abstract: |
Background: Patients with obesity often experience stigma in healthcare, which may lead to underdiagnosis or undertreatment. In the context of pain management, and migraine specifically, patients with obesity are more likely to receive both opioid and non‐opioid analgesics. However, little is known about their use of preventive treatments. Methods: We conducted a large retrospective cohort study using propensity score matching for sex and age, utilizing data from the Clalit Health Services database in Israel. The study compared newly diagnosed patients with migraine with and without obesity, identified between June 2020 and June 2023. The comparison focused on prescriptions for migraine‐specific acute medication (triptans) and preventive migraine treatments. Results: Our final analysis included 11,934 patients with migraine and obesity and 11,934 without obesity. Patients with obesity were more likely to have cardiovascular risk factors and psychiatric comorbidities. Patients with obesity were also more likely to receive acute treatment with triptans (adjusted odds ratio [aOR] 1.17, 95% confidence interval [CI] [1.11–1.23]), and preventive treatments such as topiramate (aOR 1.66, 95% CI [1.38–1.99]), gabapentinoids (aOR 1.30, 95% CI [1.13–1.50]), and duloxetine (aOR 1.42, 95% CI [1.18–1.70]), adjusting for comorbidities. Conclusion: Our findings do not support the notion that patient with migraine and obesity are undertreated; instead, they show a modest increase in prescriptions for acute and some of the preventive medications. Plain Language Summary: Patients with obesity often experience stigma in healthcare, which may lead to underdiagnosis and undertreatment. In the fields of pain and headache, patients with obesity are more likely to receive both opioid and non‐opioid analgesics, raising the question of whether they receive adequate preventive treatment. In our large‐scale study based on an analysis of a health services database in Israel, patients with migraine and obesity were not undertreated with preventative treatment and actually had a modest increase in prescriptions for both migraine‐specific acute treatment and some of the preventive treatments. [ABSTRACT FROM AUTHOR] |
|
Copyright of Headache: The Journal of Head & Face Pain is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Psychology and Behavioral Sciences Collection |
